Programmed Death-Ligand 1 (PD-L1) interacts with the Programmed Cell Death-Protein-1 (PD-1) receptor on the surface of T cells and reduces the activity of T cells, decreasing their ability to mount an effective attack against the tumor [10]. This evidence concerns the gene PDCD1 and neoplasm.